Hyperphosphatemia
diseaseOn this page
Also known as hyperphosphatemia (disease)
Summary
Hyperphosphatemia (MONDO:0000328) is a disease and 125 clinical trials. Top therapeutic interventions include sevelamer, tenapanor, and ferric citrate. A subtype of phosphorus metabolism disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 125
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | hyperphosphatemia |
| Mondo ID | MONDO:0000328 |
| MeSH | D054559 |
| DOID | DOID:0050459 |
| ICD-11 | 1745515193 |
| SNOMED CT | 20165001 |
| UMLS | C0085681 |
| MedGen | 39326 |
| Is cancer (heuristic) | no |
Also known as: hyperphosphatemia · hyperphosphatemia (disease)
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of phosphorus metabolism disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › mineral metabolism disease › phosphorus metabolism disease › hyperphosphatemia
Related subtypes (1): hypophosphatemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
4 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Calcium Acetate | Approved (phase 4) |
| Colestilan Chloride | Approved (phase 4) |
| Ferric Oxyhydroxide | Approved (phase 4) |
| Sevelamer Hydrochloride | Approved (phase 4) |
| Calcium Carbonate | Phase 3 (in late-stage trials) |
| Lanthanum Carbonate | Phase 3 (in late-stage trials) |
| Tenapanor | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 125.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 45 |
| Not specified | 36 |
| PHASE2 | 18 |
| PHASE4 | 14 |
| PHASE1 | 7 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01252771 | PHASE4 | COMPLETED | Phosphate Kinetic Modeling 2 |
| NCT01725113 | PHASE4 | TERMINATED | Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol |
| NCT01755078 | PHASE4 | COMPLETED | Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients |
| NCT02237534 | PHASE4 | UNKNOWN | Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia |
| NCT02661295 | PHASE4 | TERMINATED | A Study of Ferric Citrate to Improve Inflammation and Lipid Levels |
| NCT02836184 | PHASE4 | UNKNOWN | Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia |
| NCT03079869 | PHASE4 | COMPLETED | Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients |
| NCT03163576 | PHASE4 | UNKNOWN | The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis |
| NCT03256838 | PHASE4 | COMPLETED | Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis |
| NCT03988920 | PHASE4 | COMPLETED | A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP |
| NCT04046263 | PHASE4 | COMPLETED | Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients |
| NCT04549597 | PHASE4 | COMPLETED | Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia |
| NCT04922645 | PHASE4 | COMPLETED | Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants |
| NCT05577507 | PHASE4 | COMPLETED | Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients |
| NCT06933472 | PHASE3 | RECRUITING | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China |
| NCT00211978 | PHASE3 | COMPLETED | EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) |
| NCT00416520 | PHASE3 | COMPLETED | A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia |
| NCT00451295 | PHASE3 | TERMINATED | A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia |
| NCT00506441 | PHASE3 | COMPLETED | A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia |
| NCT00542386 | PHASE3 | COMPLETED | A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia |
| NCT00542815 | PHASE3 | COMPLETED | A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia |
| NCT00681941 | PHASE3 | COMPLETED | An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis |
| NCT00772382 | PHASE3 | COMPLETED | Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia |
| NCT00833768 | PHASE3 | TERMINATED | A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis |
| NCT00892749 | PHASE3 | COMPLETED | Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis |
| NCT01069692 | PHASE3 | COMPLETED | Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients |
| NCT01074125 | PHASE3 | COMPLETED | A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease |
| NCT01110629 | PHASE3 | COMPLETED | Study in Chronic Kidney Disease (CKD) Not on Dialysis |
| NCT01187628 | PHASE3 | COMPLETED | Long-term Study in Chronic Kidney Disease (Extension From Study 14817) |
| NCT01191255 | PHASE3 | COMPLETED | A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis |
| NCT01503736 | PHASE3 | COMPLETED | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease |
| NCT01514851 | PHASE3 | COMPLETED | Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate |
| NCT01518387 | PHASE3 | COMPLETED | Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients |
| NCT01554982 | PHASE3 | COMPLETED | A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis |
| NCT01578200 | PHASE3 | COMPLETED | Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study |
| NCT01742585 | PHASE3 | COMPLETED | A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis |
| NCT01742611 | PHASE3 | COMPLETED | Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis |
| NCT01814904 | PHASE3 | TERMINATED | Dose-finding Study of MCI-196 |
| NCT01814917 | PHASE3 | TERMINATED | Long-term Extension Study of MCI-196 |
| NCT01818687 | PHASE3 | TERMINATED | Safety and Tolerability Study of MCI-196 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SEVELAMER | 4 | 20 |
| TENAPANOR | 4 | 14 |
| FERRIC CITRATE | 4 | 13 |
| LANTHANUM CARBONATE | 4 | 8 |
| COLESTILAN CHLORIDE | 4 | 7 |
| FERRIC OXYHYDROXIDE | 4 | 7 |
| CALCIUM CARBONATE | 4 | 6 |
| NIACINAMIDE | 4 | 3 |
| SEVELAMER HYDROCHLORIDE | 4 | 3 |
| CALCIUM | 4 | 2 |
| CALCIUM ACETATE | 4 | 2 |
| CALCITRIOL | 4 | 1 |
| NIACIN | 4 | 1 |
| PARICALCITOL | 4 | 1 |
| BIXALOMER | 3 | 4 |
| BLOOD, WHOLE | 3 | 1 |
| CANDESARTAN | 3 | 1 |
| SOLNATIDE | 2 | 2 |
| CHEMBL5072826 | 0 | 2 |